Literature DB >> 23811965

Clinical profile and underdiagnosis of pulmonary hypertension in US veteran patients.

Bradley A Maron1, Gaurav Choudhary, Umar A Khan, Matthew D Jankowich, Hope McChesney, Sarah J Ferrazzani, Sainath Gaddam, Satish Sharma, Alexander R Opotowsky, Deepak L Bhatt, Thomas P Rocco, Jayashri R Aragam.   

Abstract

BACKGROUND: Pulmonary hypertension (PH) is a key contributor to cardiovascular morbidity and early mortality; however, reports are lacking on the epidemiology of PH in at-risk patient populations. METHODS AND
RESULTS: The echocardiography registries from 2 major Veterans Affairs hospitals were accessed to identify patients with at least moderate PH, defined here as a pulmonary artery systolic pressure ≥60 mm Hg detected echocardiographically. From a total of 10 471 individual patient transthoracic echocardiograms, we identified moderate or severe PH in 340 patients (332 men; mean, 77 years; mean pulmonary artery systolic pressure, 69.4±10.5 mm Hg), of which PH was listed as a diagnosis in the medical record for only 59 (17.3%). At a mean of 832 days (0-4817 days) following echocardiography diagnosing PH, 150 (44.1%) patients were deceased. PH was present without substantial left heart remodeling: the mean left ventricular ejection fraction was 0.50±0.16, left ventricular end-diastolic dimension was 5.0±0.9 cm, and left atrial dimension was 4.4±0.7 cm. Cardiac catheterization (n=122, 36%) demonstrated a mean pulmonary artery pressure of 40.5±11.4 mm Hg, pulmonary capillary wedge pressure of 22.6±8.9 mm Hg, and pulmonary vascular resistance of 4.6±2.9 Wood units. Diagnostic strategies for PH were variable and often incomplete; for example, only 16% of appropriate patients were assessed with a nuclear ventilation/perfusion scan for thromboembolic causes of PH.
CONCLUSIONS: in an at-risk patient population, PH is underdiagnosed and associated with substantial mortality. Enhanced awareness is necessary among practitioners regarding contemporary PH diagnostic strategies.

Entities:  

Keywords:  diagnosis; epidemiology; pulmonary hypertension

Mesh:

Year:  2013        PMID: 23811965      PMCID: PMC3894604          DOI: 10.1161/CIRCHEARTFAILURE.112.000091

Source DB:  PubMed          Journal:  Circ Heart Fail        ISSN: 1941-3289            Impact factor:   8.790


  25 in total

1.  Guidelines for the echocardiographic assessment of the right heart in adults: a report from the American Society of Echocardiography endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography.

Authors:  Lawrence G Rudski; Wyman W Lai; Jonathan Afilalo; Lanqi Hua; Mark D Handschumacher; Krishnaswamy Chandrasekaran; Scott D Solomon; Eric K Louie; Nelson B Schiller
Journal:  J Am Soc Echocardiogr       Date:  2010-07       Impact factor: 5.251

2.  Inaccuracy of Doppler echocardiographic estimates of pulmonary artery pressures in patients with pulmonary hypertension: implications for clinical practice.

Authors:  Jonathan D Rich; Sanjiv J Shah; Rajiv S Swamy; Anna Kamp; Stuart Rich
Journal:  Chest       Date:  2010-09-23       Impact factor: 9.410

3.  Long-term use of sildenafil in inoperable chronic thromboembolic pulmonary hypertension.

Authors:  Jay Suntharalingam; Carmen M Treacy; Natalie J Doughty; Kimberley Goldsmith; Elaine Soon; Mark R Toshner; Karen K Sheares; Rodney Hughes; Nicholas W Morrell; Joanna Pepke-Zaba
Journal:  Chest       Date:  2008-02-08       Impact factor: 9.410

4.  Evolving epidemiology of pulmonary arterial hypertension.

Authors:  Thenappan Thenappan; John J Ryan; Stephen L Archer
Journal:  Am J Respir Crit Care Med       Date:  2012-10-15       Impact factor: 21.405

5.  Protocol for vasoreactivity testing with epoprostenol in pulmonary hypertension.

Authors:  Bradley A Maron; Deepak L Bhatt; Martha Nykiel; Scott Kinlay; Aaron B Waxman
Journal:  Crit Pathw Cardiol       Date:  2012-03

6.  Current practice for determining pulmonary capillary wedge pressure predisposes to serious errors in the classification of patients with pulmonary hypertension.

Authors:  John J Ryan; Jonathan D Rich; Thejasvi Thiruvoipati; Rajiv Swamy; Gene H Kim; Stuart Rich
Journal:  Am Heart J       Date:  2012-04       Impact factor: 4.749

7.  Pulmonary hypertension.

Authors:  Sanjiv J Shah
Journal:  JAMA       Date:  2012-10-03       Impact factor: 56.272

8.  ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association.

Authors:  Vallerie V McLaughlin; Stephen L Archer; David B Badesch; Robyn J Barst; Harrison W Farber; Jonathan R Lindner; Michael A Mathier; Michael D McGoon; Myung H Park; Robert S Rosenson; Lewis J Rubin; Victor F Tapson; John Varga
Journal:  J Am Coll Cardiol       Date:  2009-04-28       Impact factor: 24.094

9.  A simple echocardiographic prediction rule for hemodynamics in pulmonary hypertension.

Authors:  Alexander R Opotowsky; Jason Ojeda; Frances Rogers; Vikram Prasanna; Mathieu Clair; Lilamarie Moko; Anjali Vaidya; Jonathan Afilalo; Paul R Forfia
Journal:  Circ Cardiovasc Imaging       Date:  2012-08-22       Impact factor: 7.792

10.  Effects of right ventricular ejection fraction on outcomes in chronic systolic heart failure.

Authors:  Philippe Meyer; Gerasimos S Filippatos; Mustafa I Ahmed; Ami E Iskandrian; Vera Bittner; Gilbert J Perry; Michel White; Inmaculada B Aban; Marjan Mujib; Louis J Dell'Italia; Ali Ahmed
Journal:  Circulation       Date:  2010-01-04       Impact factor: 29.690

View more
  30 in total

Review 1.  Metabolic reprogramming and inflammation act in concert to control vascular remodeling in hypoxic pulmonary hypertension.

Authors:  Kurt R Stenmark; Rubin M Tuder; Karim C El Kasmi
Journal:  J Appl Physiol (1985)       Date:  2015-04-30

2.  The heterogeneity of clinical practice patterns among an international cohort of pulmonary arterial hypertension experts.

Authors:  John J Ryan; Ghazwan Butrous; Bradley A Maron
Journal:  Pulm Circ       Date:  2014-09       Impact factor: 3.017

3.  Multisystem Healthcare Use among U.S. Veterans with Pulmonary Hypertension.

Authors:  Kari R Gillmeyer; Kyung M Lee; Qing Shao; Donald R Miller; Bradley A Maron; Elizabeth S Klings; Seppo T Rinne; Renda Soylemez Wiener
Journal:  Ann Am Thorac Soc       Date:  2019-08

4.  Treatment differences in pulmonary arterial hypertension management.

Authors:  Bradley A Maron; John J Ryan
Journal:  Pulm Circ       Date:  2016-12       Impact factor: 3.017

5.  Accuracy of Algorithms to Identify Pulmonary Arterial Hypertension in Administrative Data: A Systematic Review.

Authors:  Kari R Gillmeyer; Ming-Ming Lee; Alissa P Link; Elizabeth S Klings; Seppo T Rinne; Renda Soylemez Wiener
Journal:  Chest       Date:  2018-11-22       Impact factor: 9.410

6.  Derivation of a screening tool to identify patients with right ventricular dysfunction or tricuspid regurgitation after negative computerized tomographic pulmonary angiography of the chest.

Authors:  Jeffrey A Kline; Frances M Russell; Tim Lahm; Ronald A Mastouri
Journal:  Pulm Circ       Date:  2015-03       Impact factor: 3.017

Review 7.  Hemodynamics should be the primary approach to diagnosing, following, and managing pulmonary arterial hypertension.

Authors:  Bradley A Maron
Journal:  Can J Cardiol       Date:  2014-09-28       Impact factor: 5.223

Review 8.  Emerging role of angiogenesis in adaptive and maladaptive right ventricular remodeling in pulmonary hypertension.

Authors:  Andrea L Frump; Sébastien Bonnet; Vinicio A de Jesus Perez; Tim Lahm
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2017-11-02       Impact factor: 5.464

9.  Independent evaluation of a simple clinical prediction rule to identify right ventricular dysfunction in patients with shortness of breath.

Authors:  Frances M Russell; Christopher L Moore; D Mark Courtney; Christopher Kabrhel; Howard A Smithline; Kristen E Nordenholz; Peter B Richman; Brian J O'Neil; Michael C Plewa; Daren M Beam; Ronald Mastouri; Jeffrey A Kline
Journal:  Am J Emerg Med       Date:  2015-01-22       Impact factor: 2.469

10.  Beneficial effects of fenofibrate in pulmonary hypertension in rats.

Authors:  Palak Galhotra; Pankaj Prabhakar; Himanshu Meghwani; Soheb A Mohammed; Sanjay Kumar Banerjee; Sandeep Seth; Milind P Hote; K H Reeta; Ruma Ray; Subir Kumar Maulik
Journal:  Mol Cell Biochem       Date:  2018-05-14       Impact factor: 3.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.